A core outcome set for studies of gestational diabetes mellitus prevention and treatment

Thumbnail Image
125_2020_Article_5123.pdf(603.1 KB)
Published Version
125_2020_5123_MOESM2_ESM.pdf(281.94 KB)
Supplemental Material_2
125_2020_5123_MOESM1_ESM.xls(91 KB)
Supplemental Material_1
Egan, Aoife M.
Bogdanet, Delia
Griffin, Tomás P.
Kgosidialwa, O.
Cervar-Zivkovic, Mila
Dempsey, Eugene M.
Allotey, John
Alvarado, Fernanda
Clarson, Cheril
Cooray, Shamil D.
Journal Title
Journal ISSN
Volume Title
Research Projects
Organizational Units
Journal Issue
Aims/hypothesis: The aim of this systematic review was to develop core outcome sets (COSs) for trials evaluating interventions for the prevention or treatment of gestational diabetes mellitus (GDM). Methods: We identified previously reported outcomes through a systematic review of the literature. These outcomes were presented to key stakeholders (including patient representatives, researchers and clinicians) for prioritisation using a three-round, e-Delphi study. A priori consensus criteria informed which outcomes were brought forward for discussion at a face-to-face consensus meeting where the COS was finalised. Results: Our review identified 74 GDM prevention and 116 GDM treatment outcomes, which were presented to stakeholders in round 1 of the e-Delphi study. Round 1 was completed by 173 stakeholders, 70% (121/173) of whom went on to complete round 2; 84% (102/121) of round 2 responders completed round 3. Twenty-two GDM prevention outcomes and 30 GDM treatment outcomes were discussed at the consensus meeting. Owing to significant overlap between included prevention and treatment outcomes, consensus meeting stakeholders agreed to develop a single prevention/treatment COS. Fourteen outcomes were included in the final COS. These consisted of six maternal outcomes (GDM diagnosis, adherence to the intervention, hypertensive disorders of pregnancy, requirement and type of pharmacological therapy for hyperglycaemia, gestational weight gain and mode of birth) and eight neonatal outcomes (birthweight, large for gestational age, small for gestational age, gestational age at birth, preterm birth, neonatal hypoglycaemia, neonatal death and stillbirth). Conclusions/interpretation: This COS will enable future GDM prevention and treatment trials to measure similar outcomes that matter to stakeholders and facilitate comparison and combination of these studies.
Clinical diabetes , Core outcome set , Insulin therapy , Pregnancy , Systematic review
Egan, A. M., Bogdanet, D., Griffin, T. P., Kgosidialwa, O., Cervar-Zivkovic, M., Dempsey, E. M., Allotey, J., Alvarado, F., Clarson, C., Cooray, S. D., de Valk, H. W., Galjaard, S., Loeken, M. R., Maresh, M., Napoli, A., O'Shea, P. M., Wender-Ozegowska, E., van Poppel, M. N. M., Thangaratinam, S., Crowther, C., Biesty, L. M., Devane, D. and Dunne, F. P. (2020) 'A core outcome set for studies of gestational diabetes mellitus prevention and treatment', Diabetologia, 63 (6), pp. 1120-1127. doi: 10.1007/s00125-020-05123-6
Link to publisher’s version